Complement in Glomerular Disease

Advances in Chronic Kidney Disease

Volumn 19, Issue 2, 2012, Pages 84-92

  Vernon, Katherine A ^a   Cook, H Terence ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alternative pathway; Complement; Glomerular disease; Glomerulonephritis

Indexed keywords

COMPLEMENT COMPONENT C1Q; COMPLEMENT COMPONENT C1R; COMPLEMENT COMPONENT C1S; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3B; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ANCA ASSOCIATED VASCULITIS; ATYPICAL HEMOLYTIC UREMIC SYNDROME; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM; DIABETES MELLITUS; DIABETIC NEPHROPATHY; GLOMERULOPATHY; GLOMERULUS; HEMOLYTIC UREMIC SYNDROME; HOST RESISTANCE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INTERSTITIAL NEPHRITIS; MEMBRANOUS GLOMERULONEPHRITIS; PRIORITY JOURNAL; PROTEINURIA; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TISSUE INJURY;

ANIMALS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; CHRONIC DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; DIABETES MELLITUS; DISEASE PROGRESSION; FEMALE; GLOMERULONEPHRITIS; HEMOLYTIC-UREMIC SYNDROME; HUMANS; IMMUNOGLOBULIN A; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; NEPHRITIS, INTERSTITIAL; RATS;

EID: 84858781635     PISSN: 15485595     EISSN: 15485609     Source Type: Journal    
DOI: 10.1053/j.ackd.2012.02.015     Document Type: Review

References (95)

1. Go A.S., Chertow G.M., Fan D., McCulloch C.E., Hsu C.Y. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 2004, 351:1296-1305.
2. Cole D.S., Morgan B.P. Beyond lysis: how complement influences cell fate. Clin Sci (Lond) 2003, 104:455-466.
3. Wetsel R.A., Kolb W.P. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with noncomplement enzymes without release of polypeptide fragments. J Exp Med 1983, 157:2029-2048.
4. Huber-Lang M., Sarma J.V., Zetoune F.S., et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006, 12:682-687.
5. Weiler H., Isermann B.H. Thrombomodulin. J Thromb Haemost 2003, 1:1515-1524.
6. Campbell W.D., Lazoura E., Okada N., Okada H. Inactivation of C3a and C5a octapeptides by carboxypeptidase R and carboxypeptidase N. Microbiol Immunol 2002, 46:131-134.
7. Delvaeye M., Noris M., De Vriese A., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009, 361:345-357.
8. Botto M., Walport M.J. C1q, autoimmunity and apoptosis. Immunobiology 2002, 205:395-406.
9. Manderson A.P., Botto M., Walport M.J. The role of complement in the development of systemic lupus erythematosus. Annu Rev Immunol 2004, 22:431-456.
10. Botto M., Dell'Agnola C., Bygrave A.E., et al. Homozygous C1q deficiency causes glomerulonephritis associated with multiple apoptotic bodies. Nat Genet 1998, 19:56-59.
11. Robson M.G., Cook H.T., Botto M., et al. Accelerated nephrotoxic nephritis is exacerbated in C1q-deficient mice. J Immunol 2001, 166:6820-6828.
12. Seelen M.A., van der Bijl E.A., Trouw L.A., et al. A role for mannose-binding lectin dysfunction in generation of autoantibodies in systemic lupus erythematosus. Rheumatology (Oxford) 2005, 44:111-119.
13. Trouw L.A., Groeneveld T.W., Seelen M.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 2004, 114:679-688.
14. Kerr L.D., Adelsberg B.R., Schulman P., Spiera H. Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity. Arthritis Rheum 1989, 32:1406-1413.
15. Watanabe H., Garnier G., Circolo A., et al. Modulation of renal disease in MRL/lpr mice genetically deficient in the alternative complement pathway factor B. J Immunol 2000, 164:786-794.
16. Elliott M.K., Jarmi T., Ruiz P., Xu Y., Holers V.M., Gilkeson G.S. Effects of complement factor D deficiency on the renal disease of MRL/lpr mice. Kidney Int 2004, 65:129-138.
17. Sekine H., Reilly C.M., Molano I.D., et al. Complement component C3 is not required for full expression of immune complex glomerulonephritis in MRL/lpr mice. J Immunol 2001, 166:6444-6451.
18. Sheerin N.S., Springall T., Carroll M.C., Hartley B., Sacks S.H. Protection against anti-glomerular basement membrane (GBM)-mediated nephritis in C3- and C4-deficient mice. Clin Exp Immunol 1997, 110:403-409.
19. Jozsi M., Zipfel P.F. Factor H family proteins and human diseases. Trends Immunol 2008, 29:380-387.
20. Zhao J., Wu H., Khosravi M., et al. Association of genetic variants in complement factor H and factor H-related genes with systemic lupus erythematosus susceptibility. PLoS Genet 2011, 7:e1002079.
21. Fritsche L.G., Lauer N., Hartmann A., et al. An imbalance of human complement regulatory proteins CFHR1, CFHR3 and factor H influences risk for age-related macular degeneration (AMD). Hum Mol Genet 2010, 19:4694-4704.
22. Heinen S., Hartmann A., Lauer N., et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009, 114:2439-2447.
23. Atkinson C., Qiao F., Song H., Gilkeson G.S., Tomlinson S. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008, 180:1231-1238.
24. Ravirajan C.T., Wang Y., Matis L.A., et al. Effect of neutralizing antibodies to IL-10 and C5 on the renal damage caused by a pathogenic human anti-dsDNA antibody. Rheumatology (Oxford) 2004, 43:442-447.
25. Neumann I., Regele H., Kain R., Birck R., Meisl F.T. Glomerular immune deposits are associated with increased proteinuria in patients with ANCA-associated crescentic nephritis. Nephrol Dial Transplant 2003, 18:524-531.
26. Schlieben D.J., Korbet S.M., Kimura R.E., Schwartz M.M., Lewis E.J. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005, 45:758-761.
27. Xiao H., Heeringa P., Hu P., et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002, 110:955-963.
28. Xiao H., Heeringa P., Liu Z., et al. The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies. Am J Pathol 2005, 167:39-45.
29. Wirthmueller U., Dewald B., Thelen M., et al. Properdin, a positive regulator of complement activation, is released from secondary granules of stimulated peripheral blood neutrophils. J Immunol 1997, 158:4444-4451.
30. Xiao H., Schreiber A., Heeringa P., Falk R.J., Jennette J.C. Alternative complement pathway in the pathogenesis of disease mediated by anti-neutrophil cytoplasmic autoantibodies. Am J Pathol 2007, 170:52-64.
31. Vernon K.A., Pickering M.C., Cook T. Experimental models of membranoproliferative glomerulonephritis, including dense deposit disease. Contrib Nephrol 2011, 169:198-210.
32. Xing G.Q., Chen M., Liu G., et al. Complement activation is involved in renal damage in human antineutrophil cytoplasmic autoantibody associated pauci-immune vasculitis. J Clin Immunol 2009, 29:282-291.
33. Huugen D., van Esch A., Xiao H., et al. Inhibition of complement factor C5 protects against anti-myeloperoxidase antibody-mediated glomerulonephritis in mice. Kidney Int 2007, 71:646-654.
34. Beck L.H., Bonegio R.G., Lambeau G., et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009, 361:11-21.
35. Cybulsky A.V., Rennke H.G., Feintzeig I.D., Salant D.J. Complement-induced glomerular epithelial cell injury. Role of the membrane attack complex in rat membranous nephropathy. J Clin Invest 1986, 77:1096-1107.
36. Saran A.M., Yuan H., Takeuchi E., McLaughlin M., Salant D.J. Complement mediates nephrin redistribution and actin dissociation in experimental membranous nephropathy. Kidney Int 2003, 64:2072-2078.
37. Stanescu H.C., Arcos-Burgos M., Medlar A., et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011, 364:616-626.
38. Ma H, Beck LH Jr, Salant DJ. Membranous nephropathy-associated anti-phospholipase A2 receptor IgG4 autoantibodies activate the lectin complement pathway. Oral presented at: American Society of Nephrology Kidney Week; November 8-13, 2011; Philadelphia, PA.
39. Giannakakis K., Feriozzi S., Perez M., Faraggiana T., Muda A.O. Aberrantly glycosylated IgA1 in glomerular immune deposits of IgA nephropathy. J Am Soc Nephrol 2007, 18:3139-3146.
40. Bene M.C., Faure G.C. Composition of mesangial deposits in IgA nephropathy: complement factors. Nephron 1987, 46:219.
41. Roos A., Bouwman L.H., van Gijlswijk-Janssen D.J., Faber-Krol M.C., Stahl G.L., Daha M.R. Human IgA activates the complement system via the mannan-binding lectin pathway. J Immunol 2001, 167:2861-2868.
42. Roos A., Rastaldi M.P., Calvaresi N., et al. Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol 2006, 17:1724-1734.
43. Espinosa M., Ortega R., Gomez-Carrasco J.M., et al. Mesangial C4d deposition: a new prognostic factor in IgA nephropathy. Nephrol Dial Transplant 2009, 24:886-891.
44. Gharavi A.G., Kiryluk K., Choi M., et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011, 43:321-327.
45. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986. The Diabetes Control and Complications Trial Research Group.
46. Falk R.J., Sisson S.P., Dalmasso A.P., Kim Y., Michael A.F., Vernier R.L. Ultrastructural localization of the membrane attack complex of complement in human renal tissues. Am J Kidney Dis 1987, 9:121-128.
47. Halperin J.A., Taratuska A., Nicholson-Weller A. Terminal complement complex C5b-9 stimulates mitogenesis in 3T3 cells. J Clin Invest 1993, 91:1974-1978.
48. Ziyadeh F.N. The extracellular matrix in diabetic nephropathy. Am J Kidney Dis 1993, 22:736-744.
49. Acosta J., Hettinga J., Fluckiger R., et al. Molecular basis for a link between complement and the vascular complications of diabetes. Proc Natl Acad Sci U S A 2000, 97:5450-5455.
50. Qin X., Goldfine A., Krumrei N., et al. Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes. Diabetes 2004, 53:2653-2661.
51. Orchard T.J., Virella G., Forrest K.Y., Evans R.W., Becker D.J., Lopes-Virella M.F. Antibodies to oxidized LDL predict coronary artery disease in type 1 diabetes: a nested case-control study from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes 1999, 48:1454-1458.
52. Fakhouri F., Fremeaux-Bacchi V., Noel L.H., Cook H.T., Pickering M.C. C3 glomerulopathy: a new classification. Nat Rev Nephrol 2010, 6:494-499.
53. Levy M., Halbwachs-Mecarelli L., Gubler M.C., et al. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986, 30:949-956.
54. Jokiranta T.S., Solomon A., Pangburn M.K., Zipfel P.F., Meri S. Nephritogenic lambda light chain dimer: a unique human miniautoantibody against complement factor H. J Immunol 1999, 163:4590-4596.
55. Strobel S., Zimmering M., Papp K., Prechl J., Jozsi M. Anti-factor B autoantibody in dense deposit disease. Mol Immunol 2010, 47:1476-1483.
56. Pickering M.C., Cook H.T., Warren J., et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002, 31:424-428.
57. Rose K.L., Paixao-Cavalcante D., Fish J., et al. Factor I is required for the development of membranoproliferative glomerulonephritis in factor H-deficient mice. J Clin Invest 2008, 118:608-618.
58. Martinez-Barricarte R., Heurich M., Valdes-Canedo F., et al. Human C3 mutation reveals a mechanism of dense deposit disease pathogenesis and provides insights into complement activation and regulation. J Clin Invest 2010, 120:3702-3712.
59. Servais A., Fremeaux-Bacchi V., Lequintrec M., et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007, 44:193-199.
60. Levy M., Gubler M.C., Sich M., Beziau A., Habib R. Immunopathology of membranoproliferative glomerulonephritis with subendothelial deposits (Type I MPGN). Clin Immunol Immunopathol 1978, 10:477-492.
61. Neary J.J., Conlon P.J., Croke D., et al. Linkage of a gene causing familial membranoproliferative glomerulonephritis type III to chromosome 1. J Am Soc Nephrol 2002, 13:2052-2057.
62. Neary J., Dorman A., Campbell E., Keogan M., Conlon P. Familial membranoproliferative glomerulonephritis type III. Am J Kidney Dis 2002, 40:E1.
63. Gale D.P., de Jorge E.G., Cook H.T., et al. Identification of a mutation in complement factor H-related protein 5 in patients of Cypriot origin with glomerulonephritis. Lancet 2010, 376:794-801.
64. Abrera-Abeleda M.A., Nishimura C., Smith J.L., et al. Variations in the complement regulatory genes factor H (CFH) and factor H related 5 (CFHR5) are associated with membranoproliferative glomerulonephritis type II (dense deposit disease). J Med Genet 2006, 43:582-589.
65. Noris M., Remuzzi G. Hemolytic uremic syndrome. J Am Soc Nephrol 2005, 16:1035-1050.
66. Kavanagh D., Goodship T.H. Atypical hemolytic uremic syndrome, genetic basis, and clinical manifestations. Hematology Am Soc Hematol Educ Program 2011, 2011:15-20.
67. Caprioli J., Noris M., Brioschi S., et al. Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood 2006, 108:1267-1279.
68. Esparza-Gordillo J., Goicoechea de Jorge E., Buil A., et al. Predisposition to atypical hemolytic uremic syndrome involves the concurrence of different susceptibility alleles in the regulators of complement activation gene cluster in 1q32. Hum Mol Genet 2005, 14:703-712.
69. Fremeaux-Bacchi V., Miller E.C., Liszewski M.K., et al. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008, 112:4948-4952.
70. Goicoechea de Jorge E., Harris C.L., Esparza-Gordillo J., et al. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci USA 2007, 104:240-245.
71. Caprioli J., Bettinaglio P., Zipfel P.F., et al. The molecular basis of familial hemolytic uremic syndrome: mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001, 12:297-307.
72. Fremeaux-Bacchi V., Dragon-Durey M.A., Blouin J., et al. Complement factor I: a susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004, 41:e84.
73. Noris M., Brioschi S., Caprioli J., et al. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003, 362:1542-1547.
74. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J Exp Med 2007, 204:1249-1256.
75. Venables J.P., Strain L., Routledge D., et al. Atypical haemolytic uraemic syndrome associated with a hybrid complement gene. PLoS Med 2006, 3:e431.
76. de Jorge E.G., Macor P., Paixao-Cavalcante D., et al. The development of atypical hemolytic uremic syndrome depends on complement C5. J Am Soc Nephrol 2011, 22:137-145.
77. Kose O., Zimmerhackl L.B., Jungraithmayr T., Mache C., Nurnberger J. New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab. Semin Thromb Hemost 2010, 36:669-672.
78. Lapeyraque A.L., Malina M., Fremeaux-Bacchi V., et al. Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 2011, 364:2561-2563.
79. Nath K.A. The tubulointerstitium in progressive renal disease. Kidney Int 1998, 54:992-994.
80. Remuzzi G., Benigni A., Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. J Clin Invest 2006, 116:288-296.
81. Eddy A.A. Interstitial nephritis induced by protein-overload proteinuria. Am J Pathol 1989, 135:719-733.
82. Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997, 349:1857-1863. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia).
83. Lai K.N., Leung J.C., Chan L.Y., Guo H., Tang S.C. Interaction between proximal tubular epithelial cells and infiltrating monocytes/T cells in the proteinuric state. Kidney Int 2007, 71:526-538.
84. Honkanen E., Teppo A.M., Tornroth T., Groop P.H., Gronhagen-Riska C. Urinary transforming growth factor-beta 1 in membranous glomerulonephritis. Nephrol Dial Transplant 1997, 12:2562-2568.
85. Morita Y., Ikeguchi H., Nakamura J., Hotta N., Yuzawa Y., Matsuo S. Complement activation products in the urine from proteinuric patients. J Am Soc Nephrol 2000, 11:700-707.
86. Camussi G., Tetta C., Mazzucco G., Vercellone A. The brush border of proximal tubules of normal human kidney activates the alternative pathway of the complement system in vitro. Ann N Y Acad Sci 1983, 420:321-324.
87. Ichida S., Yuzawa Y., Okada H., Yoshioka K., Matsuo S. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994, 46:89-96.
88. Nangaku M., Pippin J., Couser W.G. Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome. J Am Soc Nephrol 1999, 10:2323-2331.
89. Mosolits S., Magyarlaki T., Nagy J. Membrane attack complex and membrane cofactor protein are related to tubulointerstitial inflammation in various human glomerulopathies. Nephron 1997, 75:179-187.
90. Rangan G.K., Pippin J.W., Couser W.G. C5b-9 regulates peritubular myofibroblast accumulation in experimental focal segmental glomerulosclerosis. Kidney Int 2004, 66:1838-1848.
91. Mezzano S.A., Droguett M.A., Burgos M.E., et al. Overexpression of chemokines, fibrogenic cytokines, and myofibroblasts in human membranous nephropathy. Kidney Int 2000, 57:147-158.
92. Okuda S., Oh Y., Tsuruda H., Onoyama K., Fujimi S., Fujishima M. Adriamycin-induced nephropathy as a model of chronic progressive glomerular disease. Kidney Int 1986, 29:502-510.
93. Lenderink A.M., Liegel K., Ljubanovic D., et al. The alternative pathway of complement is activated in the glomeruli and tubulointerstitium of mice with adriamycin nephropathy. Am J Physiol Renal Physiol 2007, 293:F555-F564.
94. Turnberg D., Lewis M., Moss J., Xu Y., Botto M., Cook H.T. Complement activation contributes to both glomerular and tubulointerstitial damage in adriamycin nephropathy in mice. J Immunol 2006, 177:4094-4102.
95. Boor P., Konieczny A., Villa L., et al. Complement C5 mediates experimental tubulointerstitial fibrosis. J Am Soc Nephrol 2007, 18:1508-1515.